Format

Send to

Choose Destination
Bioconjug Chem. 2010 Jan;21(1):5-13. doi: 10.1021/bc9002019.

Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.

Author information

1
Lonza Ltd, CH-3930 Visp, Switzerland. laurent.ducry@lonza.com

Abstract

Antibody-drug conjugates (ADCs) combine the specificity of monoclonal antibodies (mAbs) with the potency of cytotoxic molecules, thereby taking advantage of the best characteristics of both components. Along with the development of the mAbs and cytotoxins, the design of chemical linkers to covalently bind these building blocks is making rapid progress but remains challenging. Recent advances have resulted in linkers having increased stability in the bloodstream while allowing efficient payload release within the tumor cell.

PMID:
19769391
DOI:
10.1021/bc9002019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for American Chemical Society
Loading ...
Support Center